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Abstract
Introduction: TGF-b1 is a multi-functional cytokine that plays an important role in breast carcinogenesis. Critical role of TGF-
b1 signaling in breast cancer progression is well documented. Some TGF-b1 polymorphisms influence its expression;
however, their impact on breast cancer risk is not clear.
Methods: We analyzed 1222 samples in a candidate gene-based genetic association study on two distantly located and
ethnically divergent case-control groups of Indian women, followed by a population-based genetic epidemiology study
analyzing these polymorphisms in other Indian populations. The c.29C.T (Pro10Leu, rs1982073 or rs1800470) and c.74G.C
(Arg25Pro, rs1800471) polymorphisms in the TGF-b1 gene were analyzed using direct DNA sequencing, and peripheral level
of TGF-b1 were measured by ELISA.
Results: c.29C.T substitution increased breast cancer risk, irrespective of ethnicity and menopausal status. On the other
hand, c.74G.C substitution reduced breast cancer risk significantly in the north Indian group (p = 0.0005) and only in the
pre-menopausal women. The protective effect of c.74G.C polymorphism may be ethnicity-specific, as no association was
seen in south Indian group. The polymorphic status of c.29C.T was comparable among Indo-Europeans, Dravidians, and
Tibeto-Burmans. Interestingly, we found that Tibeto-Burmans lack polymorphism at c.74G.C locus as true for the Chinese
populations. However, the Brahmins of Nepal (Indo-Europeans) showed polymorphism in 2.08% of alleles. Mean TGF-b1 was
significantly elevated in patients in comparison to controls (p,0.001).
Conclusion: c.29C.T and c.74G.C polymorphisms in the TGF-b1 gene significantly affect breast cancer risk, which
correlates with elevated TGF-b1 level in the patients. The c.29C.T locus is polymorphic across ethnically different
populations, but c.74G.C locus is monomorphic in Tibeto-Burmans and polymorphic in other Indian populations.
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Introduction
Transforming growth factor beta (TGF-b) signaling is one of the
most commonly altered cellular pathways in human cancers [1–4].
TGF-b1 is a multi-functional cytokine that plays an important role
in breast carcinogenesis [5]. TGF-b1 is a potent inhibitor of
proliferation of epithelial, endothelial and hematopoietic cells, and
it acts as a tumor suppressor. TGF-b1 has dual role in
carcinogenesis with tumor suppressive effects in epithelial cells,
but tumor invasion and metastasis promoting effects during later
stages of carcinoma progression [6–8]. Specific pathways are
involved in the conversion of pro- and anti-tumor roles of TGF-b1
[9]. A majority of breast cancers secrete elevated TGF-b1 in
tumor micro-environment associated with either malignant
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epithelial cells, stromal cells or both [10]. Increased immuno-
reactivity for TGF-b protein correlates with poor prognosis and
increased lymph node involvement [11], and elevated TGF-b
associate with tamoxifen resistance [12]. The role of TGF-b has
been widely recognized in cancer stem cells [13,14] and TGF-b
signaling in breast cancer has been extensively reviewed [15].
Eventually, TGF-b is thought of as a potential target for
management of cancer [16–18] and inhibition of TGF-b has
been tried for treating cancer, but without significant success till
now [19–28].
TGF b are known as low penetrance genes in cancer [29].
There are three isoforms of TGF-b (TGF-b1, TGF-b2, and TGF-
b3), of which TGF- b1 is most widely expressed [30]. TGF-b1
gene is located on chromosome 19q13.1 (OMIM 190180) [31]. So
far, several polymorphisms in the TGF-b1 gene have been
reported and found to affect TGF-b1 protein expression [32].
Relationship between TGF-b1 polymorphisms and breast cancer
has been studied in several populations and is subject of further
research interest due to lack of consensus in the data [33–41]. One
of the most commonly studied polymorphisms in the TGF-b1 gene
is c.29C.T substitution (rs1800470), resulting in proline (CCG) to
leucine (CTG) change at codon 10 (Pro10Leu) of the protein (29).
Another substitution, c.74 G.C (rs1800471), resulting in replace-
ment of arginine (CGG) with proline (CCG) at codon 25
(Arg25Pro) of the protein, has been relatively less studied [42].
c.29C.T substitution results in increased secretion of cytokine
[43], making it a strong candidate for analysis in breast cancer.
These polymorphisms have not been widely analyzed in Indian
populations, except the analysis of c.29C.T polymorphism in
some Indian populations [44–46].
We conducted the present case-control study on a fairly large
sample size to; 1) investigate the association between TGF-b1
polymorphisms (c.29C.T and c.74G.C) and breast cancer risk
in India, 2) evaluate variation of the association across ethnically
different populations, 3) compare genotype frequencies of these
polymorphisms between Dravidian, Indo-European and Tibeto-
Burman populations of India, and 4) compare TGF-b1 genotypes
with other Asian populations from medico-evolutionary point of
view.
Materials and Methods
Study subjects
Ethics statement. This case-control study was carried out
with the approval of the Ethics Committee of the King George’s
Medical University, Lucknow. The subject recruitment and
sample collection were done only after obtaining written informed
consent of the participants.
The north Indian group, consisting of 113 patients and 113
control samples, was recruited from the Department of Surgery,
King George’s Medical University, Lucknow. The South Indian
group, consisting of 352 patients and 126 control samples, was
recruited from the Rai Memorial Hospital, Chennai, Nizam’s
Institute of Medical Sciences, Hyderabad, and Kasturba Medical
College, Manipal University, Manipal. Women with histopatho-
logically confirmed diagnosis of breast cancer were recruited as
cases. Women visiting the clinic for problems other than breast
cancer were recruited as controls after proper clinical investigation
and/or a mammogram confirming no evidence of breast cancer.
Women with any breast disorder or other systemic inflammatory
disease were excluded from the control group. General health
history of the cases and controls was collected with an
appropriately designed proforma. A detailed description of the
general and clinical characteristics of the patients is provided in
Table 1.
Three (Dravidian, Indo-European, and Tibeto-Burman) out of
four major linguistic groups, inhabiting the Indian mainland, have
been included in this study. After analyzing Indo-European case-
control group from northern India and Dravidian case-control
group from southern India, we extended the analysis to the
Tibeto-Burman populations from north-eastern India. Striking
differences in the allele frequency between Indian and East-Asian
(Chinese) populations [47], particularly at the c.74G.C locus
[48], encouraged us to genotype both the SNPs in Tibeto-Burman
populations, in order to further explore the medico-evolutionary
significance of TGF- b1 polymorphisms. Tibeto-Burmans in India
have close genetic affinities with East Asian populations [49]. We
recruited a total of 508 Tibeto-Burmans from north-eastern
regions of India, Nepal, and those residing in other states of India.
Samples were collected from Khasi of Meghalaya, Ao-Naga, Naga
Sema, and Chakhesang Naga of Nagaland, Nyshi of Arunachal
Pradesh, Mizo of Mizoram, Poumai Naga of Manipur, Sherpa
and Subba of Darjeeling (West Bengal), and Tibeto-Burmans
residing in Mysore (Karnataka). Since both Indo-European and
Tibeto-Burman populations inhabit Nepal, we recruited Nepali
Brahmins (Indo-European) and Magar community (Tibeto-Bur-
man) people to compare the genotype frequency with other
populations of South-East Asia.
Genotyping
Isolation of DNA for genotyping was carried out as described in
our earlier report [50]. The target TGF-b1 fragment was
amplified using primers, GAGGCCCTCCTACCTTTTG (F)
and GCAGCTTGGACAGGATCT (R), and PCR products were
analyzed on 2% agarose gel stained with ethidium bromide. The
amplified products were analyzed by direct DNA sequencing using
big dye chain terminator cycle sequencing kit (ABI) on a 3730
DNA analyzer (Applied Biosystems).
Statistical analysis
Genotype data for control population were subjected to test for
fitness in the Hardy Weinberg equilibrium. Statistical computa-
tional software available at http://ihg.gsf.de/cgi-bin/hw/hwa1.pl
was employed for this purpose. The frequencies of the two alleles
at the polymorphic sites were compared between cases and
controls to find the risk allele. Genotype data were compared using
263 contingency table of Chi Square test or Fisher’s exact test
using statistical computational tools available at http://www.
vassarstats.net. Fisher exact P values were calculated using 262 or
263 contingency tables, but wherever the software could not
calculate Fisher exact values due to large sample size, Chi Square
P value was used. Peripheral values of TGF- b1 were compared
between cases and controls using non-parametric Mann-Whitney
U-test. Age dependent multivariate Cox regression analysis was
used to assess the genotype associated risk factors of breast cancer,
considering genotypes as a risk event and socio-demographic
factors as other variables (confounder covariates). Two sided P-
values of less than 0.05 were considered significant for statistical
inference.
Results
Subject characteristics
We did not find any statistically significant difference in general
characteristics between cases and controls (Table 1). However,
slightly more number of breast cancer patients in the north Indian
group fall in the younger age group (15.93% versus 1.99%,
TGF-b1 Gene Polymorphism in Indian Women
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Table 1). More than 88% of breast cancer patients in both north
Indian and south Indian groups were sporadic. The incidence of
familial breast cancer in our subject population was quite high at
about 11% frequency, which is lower than reported in other
populations. Apparently, there was no correlation between
tobacco chewing or smoking and the incidence of breast cancer
in the study population.
TGF-b c.29C.T (codon 10) polymorphism
Genotype data were in Hardy Weinberg equilibrium for both
north Indian (F= 0.0186, Exact P= 1.0) and south Indian groups
(F = 0.0648, Exact P = 0.586). Analysis of the pooled data for all
breast cancer patients versus controls showed that C.T substi-
tution increased breast cancer risk (p = 0.00007 for allele
comparison and 0.000003 for genotype comparison) (Table 2).
Group-wise analysis showed that C.T substitution at codon 10
increased breast cancer risk both in north Indian (p= 0.0012 for
allele comparison and 0.0037 for genotype comparison) and south
Indian groups (p = 0.0413 for allele comparison and 0.0004 for
genotype comparison) (Table 3). Sub-group analysis showed that
C.T substitution increases breast cancer risk in the north Indian
group, irrespective of menopause status (Table 4). However, in
south Indians, though the association was significant in the post-
menopausal women, it is only marginally significant in pre-
menopausal women (Table 4).
TGF-b c.74G.C (codon 25) polymorphism
Genotype data for this polymorphism were found to be in
Hardy Weinberg equilibrium for both north Indian (F = 0.031,
Exact P= 0.656) and south Indian groups (F = 0.0413, Exact
P = 1.0). Analysis of the pooled data for both the study groups
showed that codon 25 polymorphism was not associated with
breast cancer risk (p = 0.063 for allele comparison and 0.165 for
genotype comparison) (Table 2). In group-wise analysis, a
significant association was observed in the north Indian group
(p = 0.0016 for allele comparison and 0.0018 for genotype
comparison) (Table 5) such that the substitution was protective
against breast cancer. However, the polymorphism showed no
association in case of south Indian group (p = 0.327 for allele
comparison and 0.554 for genotype comparison) (Table 5). In sub-
group analysis on the basis of menopause status, the difference was
significant only in the pre-menopausal group of north Indian
women (p = 0.011 for allele comparison and p=0.005 for
genotype comparison) (Table 6). However, in post-menopausal
group, no difference between cases and controls at genotype level
was seen (p = 0.104). The frequencies of the two alleles and the
genotypes at this site were comparable between south Indian cases
and controls (Table 5), and the protective effect as seen in the
north Indian group, was not evident in the South Indian group
(Tables 5 and 6).
The polymorphic status of +29C.T was comparable among
the Indo-European (North), Dravidian (South), and the Tibeto-
Burman (North-East) Indian populations (Figure 1). Interestingly,
+74G.C substitution was observed in the Indo-European and
Dravidian populations at a frequency of 5–8%, but was completely
absent in Tibeto-Burmans. Tibeto-Burmans invariably possessed
‘GG’ genotype at +74 G.C locus. The Magar group (Tibeto-
Burman) of Nepal also did not exhibit any polymorphism at this
locus. However, the Brahmins of Nepal (Indo-European) showed
polymorphism frequency comparable to other Indo-European
populations. It is clear that the polymorphism at c.29C.T locus is
very common and widespread. On the other hand, c.74G.C
locus is polymorphic in the Dravidian and Indo-European
populations, but completely monomorphic in the Tibeto-Burman
populations of India, irrespective of the location and caste status.
Serum level of TGF-b1 in breast cancer patients and
control subjects
We also measured the serum level of TGF-b1 in a subset of
cases and controls of the North Indian group (Figure 2). Peripheral
mean TGF-b1 level in the cases was significantly (U= 324.00,
p,0.001) higher in comparison to the controls (Figure 2a).
Further, the mean TGF-b1 level in cases across all three genotypes
(CC: U=72.00, p= 0.028; CT: U=3.00, p,0.001; and TT:
Table 1. Participant characteristics.
North Indian South Indian
Variables Cases (N=113) Controls (N=113) Cases (N=352) Controls (N=126)
Age (mean6SD) 45.42615.56 41617.30 49.52613.32 49.21611.71
BMI (Kg/m2) 21.6466.21 23.1965.14 20.1865.70 21.1965.71
Age at menarche (years, mean 6 SD) 14.1561.87 14.1262.10 13.5961.87 13.5161.88
Age at diagnosis for cases or at interview for controls
#30 years 18 (15.93%) 12 (10.62%) 7 (1.99%) 8 (6.35%)
31–45 years 36 (31.86%) 48 (42.48%) 109 (30.97%) 44 (34.92%)
46–60 years 38 (33.63%) 33 (29.20%) 155 (44.03%) 52 (41.27%)
61–75 years 15 (13.27%) 14 (12.39%) 75 (21.31%) 19 (15.08%)
76–90 years 6 (5.31%) 6 (5.31%) 6 (1.71%) 3 (2.38%)
Family history
Positive 13 (11.50%) 0 (0%) 40 (11.36%) 0 (0%)
Negative 100 (88.50%) 113 (100%) 312 (88.64%) 126 (100%)
Tobacco chewing/smoking habit
Yes 12 (10.62%) 5 (4.42%) 16 (4.55%) 4 (3.17%)
No 101 (89.38%) 108 (95.58%) 336 (95.55%) 122 (96.83%)
doi:10.1371/journal.pone.0075979.t001
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U=11.00, p = 0.042) at +29 C.T polymorphism was also found
to be significantly higher as compared to the controls (Figure 2b).
In contrast, the GG genotype at +74G.C polymorphism showed
significantly (U= 212.00, p,0.001) higher mean TGF-b1 level in
cases as compared to controls, but TGF-b1 level in case of
Table 2. Pooled data comparison for all cases versus controls.
All subjects (Codon 10)
Alleles
C T Comparison OR (95% CI)
Cases 335 (36.10) 593 (63.90) Fisher exact P = 0.00007* 1.58 (1.26–1.98)
Controls 225 (47.27) 251 (52.73)
Genotype
CC CT TT Comparison OR (95% CI)
Cases 85 (18.32) 165 (35.56) 214 (46.12) Chi Square P = 0.000003* —
Controls 51 (21.43) 123 (51.68) 64 (26.89)
All subjects (Codon 25)
Alleles
G C Comparison OR (95% CI)
Cases 881 (94.73) 49 (5.27) Chi Square P = 0.0636 0.66 (0.42–1.02)
Controls 439 (92.23) 37 (7.77)
Genotype
GG GC CC Comparison OR (95% CI)
Cases 419 (90.11) 43 (9.25) 3 (0.64) Chi Square P = 0.1653 —
Controls 203 (85.29) 33 (13.87) 2 (0.84)
Allele and genotype frequency is followed by percent values in parenthesis.
*Indicates statistical significant value at 95% level of confidence.
doi:10.1371/journal.pone.0075979.t002
Table 3. +29 C.T polymorphism allele and genotype data comparison between cases and controls.
North Indian group
Alleles
C T Comparison OR (95% CI)
Cases 80 (35.71) 144 (64.28) Fisher exact P = 0.0012* 1.89(1.30–2.77)
Controls 115 (51.33) 109 (48.66)
Genotype
CC CT TT Comparison OR (95% CI)
Cases 16 (14.28) 48 (42.85) 48(42.85) Fisher exact P = 0.0037* —
Controls 29 (25.89) 57 (50.89) 26(23.21)
South Indian group
Alleles
C T Comparison OR (95% CI)
Cases 255 (36.22) 449 (63.77) Fisher exact P = 0.0413* 1.36 (1.02–1.83)
Controls 110 (43.65) 142 (56.34)
Genotype
CC CT TT Comparison OR (95% CI)
Cases 69(19.60) 117(33.23) 166(47.15) Chi Square P = 0.0004* —
Controls 22(17.46) 66(52.38) 38(30.15)
Allele and genotype frequency is followed by percent values in parenthesis.
*Indicates statistical significant value at 95% level of confidence.
doi:10.1371/journal.pone.0075979.t003
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Table 4. Comparison of +29 C.T genotype data between case groups as per menopause and the controls.
North Indian group
Controls (112)
Pre-menopausal
patients (65) P value, OR (95% CI)
Post-menopausal
patients (47) P value, OR (95%CI)
Alleles
C 115(51.33) 46(35.38) Fisher exact P = 0.004*,
1.93 (1.23–3.00)
34(36.17) Fisher exact P = 0.014*,
1.86 (1.13–3.06)
T 109(48.66) 84(64.61) 60(63.82)
Genotypes
C/C 29(25.89) 8(12.30) Fisher exact P = 0.015* 8(17.02) Fisher exact P = 0.029*
C/T 57(50.89) 30(46.15) 18(38.29)
T/T 26(23.21) 27(41.53) 21(44.68)
South Indian Group
Controls (126)
Pre-menopausal
patients (128) P value, OR (95%CI)
Post-menopausal
patients (224) P value, OR (95%CI)
Alleles
C 110(43.65) 100(39.06) Fisher exact P = 0.321,
1.21 (0.85–1.72)
155(34.59) Fisher exact P = 0.018*,
1.46 (1.07–2.01)
T 142(56.34) 156(60.93) 293(65.40)
Genotypes
CC 22(17.46) 26(20.47) Fisher exact P = 0.043* 43(19.11) Chi Square P = 0.0002*
CT 66(52.38) 47(37.00) 70(31.11)
TT 38(30.15) 54(42.51) 112(49.77)
Allele and genotype frequency is followed by percent values in parenthesis.
*Indicates statistical significant value at 95% level of confidence.
doi:10.1371/journal.pone.0075979.t004
Table 5. Comparison of +74 G.C genotype data between cases and controls.
North Indian group
Alleles
G C Comparison OR (95% CI)
Cases 217 (96.017) 9 (3.98) Fisher exact P = 0.0016* 0.30 (0.14–0.66)
Controls 197 (87.94) 27 (12.053)
Genotype
GG GC CC Comparison OR (95% CI)
Cases 105(92.92) 7(6.19) 1 (0.88) Fisher exact P = 0.0018* —
Controls 87(77.67) 23(20.53) 2 (1.78)
South Indian group
Alleles
G C Comparison OR (95% CI)
Cases 664 (94.31) 40 (5.68) Fisher exact P = 0.327 1.45 (0.72–2.96)
Controls 242 (96.03) 10 (3.96)
Genotype
GG CG CC Comparison OR (95% CI)
Cases 314(89.204) 36(10.227) 2(0.568) Chi Square P = 0.554 —
Controls 116(92.06) 10(7.936) 0(0)
Allele and genotype frequency is followed by percent values in parenthesis.
*Indicates statistical significant value at 95% level of confidence.
doi:10.1371/journal.pone.0075979.t005
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CG+CC genotypes did not differ significantly between the two
groups (U= 9.00, p = 0.630, Figure 2c).
Association of TGF-b polymorphism with covariates
To determine the predictors (covariates) of breast cancer risk,
genotype data for both the polymorphisms (c.29C.T and
c.74G.C) of North Indians were further analyzed by multivariate
Cox regression (Table 7). None of the investigated covariates
showed significant association with genotypes associated breast
cancer risk, except the menopausal status. The menopausal status
in both the polymorphisms showed significant (p,0.001) associ-
ation with breast cancer risk.
Discussion
We observed that the c.29C.T substitution at codon 10 of the
TGF-b1 gene significantly increases the risk of breast cancer in
Indian populations. The patients exhibited a far higher frequency
of the substitution in comparison to the controls. We found that
the allele frequency at this locus in Indian populations is
comparable to other populations across the globe (refer NCBI
database). In sub-group analysis, we found this substitution to
increase breast cancer risk irrespective of ethnicity, as both North-
and South-Indian women having substitution were at an increased
risk of breast cancer. Comparison of the pre-menopausal and post-
menopausal cases with all controls suggested that c.29C.T
substitution increases breast cancer risk irrespective of the
menopausal status. Three other studies from India have analyzed
c.29C.T locus in breast cancer [44–46]. Two of them reported
no association of this polymorphism with breast cancer risk
[44,45]; however, Joshi et al. (2011) reported that TGF-b1 *29C
was protective against breast cancer and suggested this to be a
plausible reason behind relatively lower incidence of breast cancer
in western Indian women in comparison to white women [46].
The allele and genotype frequencies in our study were comparable
to those in Joshi et al (2011), and the data support that *29C is a
protective allele and *29T a risk allele. Nevertheless, it is worth
noting that our inference is in contrast to two other studies from
India [44,45].
Published data on c.29C.T polymorphism in breast cancer
lack consensus. As a result, five meta-analyses have been
conducted on this polymorphism. Interestingly, all five meta-
analyses were published in the same year [29,42,51,52,53]. Two of
these meta-analysis stated no association between c.29C.T
polymorphism and breast cancer [29,51], while the two others
stated no overall association between this substitution and breast
cancer risk, but an increased risk of breast cancer with 10P allele in
Caucasians [42,52], and yet another meta-analysis stated signif-
icant association of 10P in overall analysis as well as in the
Caucasian group [53]. Contrary to the observations of all these
meta-analyses, particularly the latter three, we found the alternate
allele (‘T’ or ‘leucine’) to be a risk factor for breast cancer. Our
results have infused further curiosity regarding the association of
this polymorphism with breast cancer.
We observed that c.74G.C substitution was significantly
protective against breast cancer in the north Indian population
only. North Indian patient population exhibited a higher
frequency of the substitution in comparison to the controls. Sub-
grouping of North Indian cases according to the menopausal status
revealed significant protective effect of this substitution in case of
pre-menopausal women only. A clear ethnicity based impact on
breast cancer risk of the genotypes at c.74G.C site was evident, as
Table 6. Comparison of +74 G.C genotype data between case groups as per menopause and the controls.
North Indian group
Controls (112)
Pre-menopausal
patients (65) P value, OR (95% CI)
Post-menopausal
patients (48) P value, OR (95%CI)
Alleles
G 197(87.94) 125(96.15) Fisher exact P = 0.011*,
0.29 (0.11–0.78)
92(95.83) Fisher exact P = 0.037*,0.32 (0.11–
0.93)
C 27(12.05) 5(3.84) 4(4.16)
Genotypes
GG 87(77.67) 61(93.84) Fisher exact P = 0.005* 44(91.66) Fisher exact P = 0.104
GC 23(20.53) 3(4.61) 4(8.33)
CC 2(1.78) 1(1.53) 0(0)
South Indian Group
Controls (126)
Pre-menopausal
patients (127) P value, OR (95%CI)
Post-menopausal
patients (225) P value, OR (95%CI)
Alleles
G 136(93.15) 236(92.91) Fisher exact P = 1.000,
1.03 (0.46–2.31)
428(95.11) Fisher exact P = 0.397,0.69 (0.32–
1.51)
C 10(06.84) 18(07.62) 22(4.88)
Genotypes
GG 116(92.06) 111(87.40) Fisher exact P = 0.264 203(90.22) Chi square P = 0.847
GC 10(7.93) 14(11.02) 22(9.77)
CC 0(00.00) 2(1.57) 0(00.00)
Allele and genotype frequency is followed by percent values in parenthesis.
*Indicates statistical significant value at 95% level of confidence.
doi:10.1371/journal.pone.0075979.t006
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the protective effect of ‘CC’ genotype was not seen in the South
Indian group. This polymorphism has been relatively less studied
in comparison to c.29C.T substitution. Only one study on breast
cancer from India has analyzed this polymorphism, finding no
significant difference between cases and controls [44]; however,
this study had severely low statistical power due to the use of a very
small sample size for inference. Two other Indian studies on TGF-
b1 polymorphisms in breast cancer did not analyze this
polymorphism [45,46]. We are the first to genotype this
polymorphism in a significantly large sample size and report
protective effect of the substitution. Our analysis on Tibeto-
Burman populations of India found no variation at this locus. This
observation is interesting, but not surprising, as one of our earlier
studies showed complete absence of a 25 bp deletion polymor-
phism in the MyBPC3 gene (causing various forms of cardiomy-
opathy) in these populations despite its presence in almost all other
Indian populations at about 4% frequency [47]. Shanghai breast
cancer study also found no incidence of sequence variation at
c.74G.C locus after analysis on a cohort of 1111 Chinese patients
[48]. Most other populations across the world exhibit small
frequency of ‘C’ allele, showing widespread existence of this
polymorphism (refer NCBI database).
Highly polymorphic status of the c.29C.T locus among Indian
and North-Eastern Indian populations shows widespread existence
of this polymorphism. Monomorphism at the c.74G.C locus
unveils important medical and evolutionary significance associated
with this locus. The absence of the protective allele (C) may suggest
relatively higher risk of breast cancer in the Tibeto-Burmans in
comparison to the Dravidians and Indo-Europeans. Similarly, the
absence of ‘C’ allele in the Chinese populations may indicate
increased breast cancer risk in comparison to the Indian
populations. This notion is supported by a higher incidence of
breast cancer in the Chinese populations in comparison to the
Indian populations (Dravidian) as reported in an epidemiological
study comparing breast cancer incidence over a period of three
decades [54]. From evolutionary point of view, our data further
supports the proposal that the people of north-eastern region of
Indian are genetically closer to Chinese/East Asian populations
[49].
We observed that TGF-b1 level in the breast cancer patients
was significantly elevated as compared to the control group. The
elevated TGF-b1 level could be due to a higher frequency of the
risk genotypes in the cases. Further analysis on the basis of
genotypes suggested that TGF-b1 level of cases in comparison to
control was significantly higher in all the genotypes of c.29C.T
locus, while in case of c.74G.C locus, it was only significant in
absence of ‘‘C’’ allele. Intra-tumoral expression of TGF-b1 has
been found to be significantly higher in invasive breast cancer
patients [55]. It is well documented that TGF-b1 polymorphic
variants are functionally associated with the level of TGF-b1
expression [40,56–57]. Therefore, it is plausible that TGF-b1
polymorphisms affect breast cancer risk by modulating the level of
TGF-b1 expression. In multistage progression of tumors, TGF-b
exerts growth inhibitory effects in the initial phase; however,
growth-inhibitory effects are abolished and malignant tumor
promoting action of TGF-b is activated in the later stages [58].
Significant correlation of TGF-b1 allelic variants with elevated
TGF-b1 level suggests their critical role in deciding cancer
initiation and progression. Nevertheless, a direct correlation
between allelic variants, the level of expression, and cancer risk
or progression is difficult to derive since the level of TGF- b1
expression and its pro- and anti-apoptotic effects may differ at
different stages of cancer progression. A stage specific analysis of
the TGF- b1 expression level and haplotype analysis of all the
polymorphisms of this locus could help further understand the
breast cancer risk associated with TGF-b1 variations. We feel that
availability of further details such as ER and HER2 status,
treatment outcome, recurrence rate, and drug resistance data
could have helped undertake further detailed investigations, which
could not be undertaken due to unavailability of such data.
In conclusion, c.29C.T substitution increases breast cancer
risk irrespective of ethnicity and menopausal status. This
Figure 1. Distribution of the two polymorphisms in Indian populations.
doi:10.1371/journal.pone.0075979.g001
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polymorphism is quite common across the world. c.74G.C
polymorphism, on the other hand, showed ethnic variations such
that the substitution decreased breast cancer risk in the north
Indian populations, but not in their south Indian counterparts.
This could be due to a significant impact of other co-occurring
genetic variations affecting the risk due to this polymorphism. In
other words, the genetic background perhaps becomes more
influential in case of c.74G.C polymorphism. The c.74G.C
locus is polymorphic across the world with moderate frequency of
‘CC’ genotype, except in case of the North-East Indians, Nepalese,
and Chinese populations. Monomorphism at this locus may
suggest increased breast cancer risk in these populations in
comparison to other ethnic groups. The increased level of TGF-
b1 in the patients in comparison to the controls could suggest the
possible mechanism of the effect of TGF-b1 polymorphisms on
breast cancer. However, further in vitro studies are required in
order to decipher the mechanism of increased cancer risk in the
carriers of certain TGF-b1 genotypes. Significant impact of
c.74G.C polymorphism on breast cancer risk encourages more
studies on this polymorphism. In addition to identifying genetic
risk factors for breast cancer, our study has revealed striking
differences in the genetic variations between different ethnic
groups, which could have important implications on human
health.
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Figure 2. Peripheral level of TGF-b1 (a) in cases and controls,
.T and (c) c.74G.C locus.
Significance level: non-significant - p.0.05, *- p,0.05, ***- p,0.001.
doi:10.1371/journal.pone.0075979.g002
Table 7. Age dependent associations of genotypes with
confounding covariates in north Indian population by Cox
regression analysis.
Predictors +29C.T +74G.C
OR (95% CI) P value OR (95% CI) P value
BMI 1.15 (0.67–1.97)0.608 1.15 (0.68–1.97)0.602
Diet 1.07 (0.62–1.85)0.814 1.07 (0.63–1.83)0.802
Relation 1.35 (0.55–3.30)0.508 1.36 (0.56–3.30)0.499
Family type 1.00 (0.46–2.15)0.998 1.00 (0.46–2.14)0.995
Personal habits 0.95 (0.43–2.13)0.905 0.95 (0.43–2.12)0.901
Age at
menarche
0.80 (0.44–1.43)0.444 0.79 (0.44–1.42)0.435
Age at 1st full
term
pregnancy
0.83 (0.50–1.38)0.469 0.83 (0.50–1.37)0.460
Menopausal
status
3.38 (1.77–6.46),0.001* 3.43 (1.80–6.52),0.001*
The odds are of BMI ‘‘.23 kg/m2, Diet ‘‘Non vegetarian’’, Religion ‘‘Hindu’’,
Family history ‘‘Yes’’, Personal habits ‘‘Yes’’, Age at menarche ‘‘.14 yrs), Age at
1st full term pregnancy ‘‘.19 yrs’’ and Menopausal status ‘‘Yes’’ against BMI
‘‘#23 kg/m2, Diet ‘‘Vegetarian’’, Religion ‘‘Muslim’’, Family history ‘‘No’’,
Personal habits ‘‘No’’, Age at menarche ‘‘#14 yrs), Age at 1st full term
pregnancy ‘‘#19 yrs’’ and Menopausal status ‘‘No’’.
*Statistically significant (p,0.001).
doi:10.1371/journal.pone.0075979.t007
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(b) according to genotypes at c.29C
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